(19)
(11) EP 3 377 040 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
05.06.2024 Bulletin 2024/23

(45) Mention of the grant of the patent:
06.03.2024 Bulletin 2024/10

(21) Application number: 16809255.9

(22) Date of filing: 18.11.2016
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61P 43/00(2006.01)
C23C 16/40(2006.01)
C23C 16/505(2006.01)
 A61P 27/02(2006.01)
C23C 16/04(2006.01)
A61M 5/31(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0048; C23C 16/045; C23C 16/401; C23C 16/505; A61M 2005/3131; A61P 27/02; A61P 43/00
(86) International application number:
PCT/US2016/062885
(87) International publication number:
WO 2017/087871 (26.05.2017 Gazette 2017/21)

(54)

PHARMACEUTICAL PACKAGE FOR OPHTHALMIC FORMULATIONS

PHARMAZEUTISCHE VERPACKUNG FÜR OPHTHALMISCHE FORMULIERUNGEN

EMBALLAGE PHARMACEUTIQUE POUR FORMULATIONS OPHTALMIQUES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.11.2015 US 201562257208 P

(43) Date of publication of application:
26.09.2018 Bulletin 2018/39

(73) Proprietor: SiO2 Medical Products, Inc.
Auburn, AL 36832 (US)

(72) Inventors:
  • WEIKART, Christopher
    Auburn, Alabama 36830 (US)
  • BENNETT, Murray Stephen
    Bellingham, Washington 98225 (US)
  • GIRAUD, Jean-Pierre
    Auburn, Alabama 36830 (US)

(74) Representative: Maiwald GmbH 
Elisenhof Elisenstraße 3
80335 München
80335 München (DE)


(56) References cited: : 
WO-A1-2014/005728
 WO-A1-2014/164928
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).